Zusammenfassung
Einleitung: Das Persistieren der Symptome eines Aufmerksamkeitsdefizit-Hyperaktivitäts-Syndroms
(ADHS) ins Erwachsenenalter erhöht das Risiko zur Entwicklung einer Abhängigkeit.
Genetische Faktoren erklären 50 - 70 % der Varianz eines ADHS, aber auch einer Alkoholabhängigkeit.
Das serotonerge System könnte entscheidend an der Pathogenese beider Erkrankungen
beteiligt sein. Methodik: Populationsbasierte Assoziationsuntersuchung des Promotorpolymorphismus im Serotonin-Transporter-Gen
(5-HTT) und des Cys23Ser-Polymorphismus des 5-HT2c-Rezeptors bei 314 deutschstämmigen
Alkoholabhängigen. Ergebnis: 21 % der Alkoholabhängigen zeigten ein ADHS im Erwachsenenalter (DSM-IV). Es zeigten
sich keine signifikanten Unterschiede in der Verteilung des 5-HTT-Genotyps bzw. der
5-HT2c-Allele zwischen ADHS-positiven und -negativen Alkoholabhängigen bzw. gesunden
Kontrollen. Schlussfolgerung: Der putative pathogenetische Beitrag des serotonergen Systems zur Alkoholabhängigkeit
und einem AHDS lässt sich nicht auf die von uns gewählten Kandidatengene (5-HTT; 5-HT2c)
zurückführen.
Abstract
Introduction: Nearly 50 % of subjects with continuing symptoms of attention-deficit hyperactivity
disorder (ADHD) in adulthood show a comorbid substance use disorder. Both, ADHD and
alcohol dependence have a high genetic load and might even share overlapping sources
of genetic liability. Method: We investigated phenotype and 5-HTT/5-HT2c allelic characteristics in 314 alcoholics
of German descent. Result: 21 % of the alcoholics fulfilled DSM-IV-criteria of ADHD with ongoing symptoms in
adulthood. There was no significant difference in 5-HTT- or 5-HT2c-allele distribution
between alcoholics and matched controls or between alcoholics with or without ADHD.
Conclusion: In our sample the functional relevant 5-HTT-promoter and the 5-HT2c-receptor Cys23Ser
polymorphism do not contribute to the supposed common genetic predisposition of ADHD
and alcohol dependence.
Literatur
- 1
Mannuzza S, Klein R G, Bessler A, Malloy P, LaPadula M.
Adult outcome of hyperactive boys. Educational achievement, occupational rank, and
psychiatric status.
Archives of General Psychiatry.
1993;
50
565-576
- 2
Sullivan M A, Rudnik-Levin F.
Attention deficit/hyperactivity disorder and substance abuse. diagnostic and therapeutic
considerations.
Annals of the New York Academy of Sciences.
2001;
931
251-270
- 3
Prescott C A, Kendler K S.
Genetic and environmental contributions to alcohol abuse and dependence in a population-based
sample of male twins.
Am J Psychiatry.
1999;
156
34-40
- 4
Higley J D, Suomi S J, Linnoila M.
A nonhuman primate model of type II alcoholism? Part 2. Diminished social competence
and excessive aggression correlates with low cerebrospinal fluid 5-hydroxyindoleacetic
acid concentrations.
Alcohol Clin Exp Res.
1996;
20
643-650
- 5
Gainetdinov R R, Wetsel W C, Jones S R, Levin E D, Jaber M, Caron M G.
Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity.
Science.
1999;
283
397-401
- 6
Comings D E, Gade-Andavolu R, Gonzalez N, Wu S, Muhleman D, Blake H, Chiu F, Wang E,
Farwell K. et al .
Multivariate analysis of associations of 42 genes in ADHD, ODD and conduct disorder.
Clinical Genetics.
2000;
58
31-40
- 7
Spivak B, Vered Y, Yoran-Hegesh R, Averbuch E, Mester R, Graf E, Weizman A.
Circulatory levels of catecholamines, serotonin and lipids in attention deficit hyperactivity
disorder.
Acta Psychiatr Scand.
1999;
99
300-304
- 8
Schulz K P, McKay K E, Newcorn J H, Sharma V, Gabriel S, Halperin J M.
Serotonin function and risk for alcoholism in boys with attention-deficit hyperactivity
disorder. Neuropsychopharmacology.
Official Publication of the American College of Neuropsychopharmacology.
1998;
18
10-17
- 9
Weijers H G, Wiesbeck G A, Jakob F, Boning J.
Neuroendocrine responses to fenfluramine and its relationship to personality in alcoholism.
Journal of Neural Transmission General Section.
2001;
108
1093-1105
- 10
Coccaro E F, Kavoussi R J, Oakes M, Cooper T B, Hauger R.
5-HT2a/2c receptor blockade by amesergide fully attenuates prolactin response to d-fenfluramine
challenge in physically healthy human subjects.
Psychopharmacologia.
1996;
126
24-30
- 11
Reist C, Mazzanti C, Vu R, Tran D, Goldman D.
Serotonin transporter promoter polymorphism is associated with attenuated prolactin
response to fenfluramine.
American Journal of Medical Genetics.
2001;
105
363-368
- 12
Wittchen H-U.
Reliability and validity studies of the WHO-Composite International Diagnostic Interview
(CIDI): a critical review.
Journal of Psychiatric Research.
1994;
28
57-84
- 13
Gross J, Blocher D, Trott G E, Rosler M.
Assessment of the attention-deficit hyperactivity disorder in adults.
Der Nervenarzt.
1999;
70
20-25
- 14
Johann M, Bobbe G, Putzhammer A, Wodarz N.
Comorbidity of alcohol dependence with attention-deficit hyperactivity disorder: differences
in phenotype with increased severity of the substance disorder, but not in genotype
(serotonin transporter and 5-hydroxytryptamine-2c receptor).
Alcoholism Clinical and Experimental Research.
2003;
27
1527-1534
- 15
Seeger G, Schloss P, Schmidt M H.
Functional polymorphism within the promotor of the serotonin transporter gene is associated
with severe hyperkinetic disorders.
Molecular Psychiatry.
2001;
6
235-238
- 16
Retz W, Thome J, Blocher D, Baader M, Rösler M.
Association of attention deficit hyperactivity disorder-related psychopathology and
personality traits with the serotonin transporter promoter region polymorphism.
Neuroscience Letters.
2002;
319
133-136
- 17
Manor I, Eisenberg J, Tyano S, Sever Y, Cohen H, Ebstein R P, Kotler M.
Family-based association study of the serotonin transporter promoter region polymorphism
(5-HTTLPR) in attention deficit hyperactivity disorder.
American Journal of Medical Genetics.
2001;
105
91-95
- 18
Zoroglu S S, Erdal M E, Alasehirli B, Erdal N, Sivasli E, Tutkun H, Savas H A, Herken H.
Significance of serotonin transporter gene 5-HTTLPR and variable number of tandem
repeat polymorphism in attention deficit hyperactivity disorder.
Neuropsychobiology.
2002;
45
176-181
Dr. Norbert Wodarz
Psychiatrische Klinik der Universität · Klinische Suchtmedizin
Universitätsstraße 84
93042 Regensburg
eMail: norbert.wodarz@medbo.de